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ATTEMPTS to induce antitumour pro-
tection with syngeneic tumour cells
treated with glutaraldehyde (GA) have
been reported by numerous workers.
Induction of antitumour protection was
reported in some cases (Csaba, 1967;
Powell, 1975; Sanderson & Frost, 1974;
Frost & Sanderson, 1975; Frost et al.,
1976; Kataoka et al., 1975, 1977a, b, 1978,
1979a, b, c, d; Tomecki, 1979) whereas in
other systems no protection was achieved
(Kluchareva et al., 1978; Price et al., 1979).
The use ofGA was based on its property as
a stabilizer of the cell surface by virtue of
its activity as a protein cross-linking
reagent (Richard & Knowles, 1968). It has
TABLE. Immunization of BALB/c mice with GA-treated MIOPC-315 plasmacytoma cells
Pool No. of No. of
Number Expts groups*
I 5 9
5
II 3 9
3
III 3 7
:3
IV 2 4
9
V 3 5
3
VI 5 7
5
I
1I
5
3
9
9
Immunization
procedure**
First
No. injection + e/
inj. (%GA) total
2or 4 0-08§ 89/116
52/52
0-08 51/66
32/32
2 or 4 0 03 to 48/58
0-06§§ 29/30
1 0-06 18,/25
20/20
004 27/33
29/30
1 0-02 56/57
49/50
2 or 4 0-08 89/116
1 0-08 51/66
Take
AITI)t
(days)
27 7
14-4
230
14-0
24 1
15-:3
23-8
15-7
23 0
15-8
15-2
15-5
27 7
23 0
MIortalitytt
AI .NI
Pttt (days) P
<0.001 404 <0001
30-1
<001 37-8 <001
29-9
<0001 37-9 <(0001
2995
<(005 38-7 <0.05
31-8
<0-02 38-2 <0 02
30 5
NS 31-0 NS
30 4
<0(05 404 NS
27-8
* 5-20 mice per group.
** All injections were given s.c.; cells tieated withl 002% GA were used forl ast immtunization; immuniiza-
tion: 5 x 105 to 5 x 106 cells per mouse; challenge: 104 xviable ttumour (ells.
t MTD mean time to tumour detection.
tt All tumour-bearing animals died during observation; AITM mean time of mortality.
§ Cells treated with 0-06% GA and 0-04% GA were used stubsequently in 6 groups receivxing intermediate
iInjections.
§§ Cells treated witlh 0.033% GA were used for the intermeciate injection in groups receiving 3 injections
(2 groups); intermediate injections of 0.04% GA-treated andl 0.03% GA-treated cells were given in groups
receiving 4 injections (2 groups).
ttt P-degree of significance was calculated by Student's t test; significant protection w,as obtained in
8/9 indivTidual groups of Pool I, 5/9 of Pool II, 4/7 Pool III, 2/4 of Pool IV, 1/5 of Pool V and 0/7 of Pool VI..AIMMUNOPROPHYLAXIS BY GLUTARALDEHYDE-TREATEI) TUMOUR CELLS
also been claimed that modification of
cells by GA reduced the antibody response,
whereas the cellular response was main-
tained and even increased (Dennert &
Tucker, 1972; Parish, 1972). Preferential
elicitation of cell-mediated immutnity was
assumed to be advantageous for induc-
tion of specific protective immunization
against tumours (Mitchison, 1.970).
The present study was undertaken to
investigate the possibility of induction of
antitumour protection against murine
myeloma MOPC-315 in syngeneic BALB/c
mice by use of GA-treated cells. The
MOPC-315 myeloma cell line is derived
from primary plasmacytoma tumour in-
duced in mice of the BALB/c strain by
i.p. administration of Bayol F, develops
exclusively in this strain and is character-
ized by its ability to secrete anti-TNP
IgA A2immunoglobulin (Eisen etal., 1968).
This tumour cell line is highly tumorigenic
by either i.p. or s.c. injection, and has been
reportedasweakly immunogenic (WVilliams
& Kruger, 1972).
Suspensions ofMOPC-315 cells prepared
from s.c. induced tumours were used in all
the experiments. The treatment with GA
was performed by mixing volumes of
0*2 ml of cell suspensions (2 x 107 viable
cells/ml) in PBS at pH 7-2 with 1*8 ml GA
solution (TAAB, England), for 10 min at
room temperature. The treated cells were
washed by 3 subsequent centrifugations at
100 g for 7 min at 4°C. Packed cells were
resuspended either in Eagle's medium
for thymidine (dT) incorporation mea-
surements (Diamantstein & Ulmer, 1975)
or in PBS for injections. The results in
Fig. IA show that treatment of cells
by a solution of 0.00125% GA led to a
marked decrease in (dT) incorporation
whilst GA concentrations of 0-01-0.08%
almost completely inhibited the incorpora-
tion. As shown in the same figure, the
viability of cells, as measured by trypan-
blue dye exclusion, was less affected by
GA; marked reduction was obtained only
at a concentration of at least 0 06% GA.
MOPC-315 cells treated with less than
0*01'% GA retained their ability to induce
tumours. Partial loss of this ability (delay
in development of tumours and reduction
in mortality) was seen after treatment
with 0.01-0.02% CXA (Fig. IB). Complete
loss of the capacity to induce tumour was
achieved by treatment with 0 06-0 08%
GA (results not shown here). In thispar-
ticular case, the cell suspension used was
the same as in the experiment illustrated
in Fig. IA.
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FIG. I. Effect of treatment witlh various Con-
centrations of GA on MIOPC-315 cells origi-
nate(t from s.c. iin(luce(t tumours; 4 x 1O0
cells/0-2 ml 'were mixe(d witlh 1-8 ml of
GA soluition aindl inicubated for 10 mill at
room temperature. A GA-treatedl cells
subcultured for 24 hi; [3H]-dT addedl 6 hi
before the endl ofincubation time. C 0,, of
[3H]-dT incorporation (levels in untreated
ctultures (2797+496) takeni as 100%).
0-0 viability (levels in untreated cuLltures
taken as 1000o). B-Tumorigenicity of
GA-treatecl cells; 5 x 105 cells per mouse
s.C.; 8-10 mice per group. GA concentration
(Mo): - - - 0-02; + + + 0-01; 0-005;
noIl(c
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FIG. 2.-Protective effect ofs.e. injection (21 and 7 days before challenge) with GA-treated MOPC-315
cells (5 x 105/injection) originated from s.c. tumour; Challenge of 104viablecellsgiven s.c. 7 daysafter
the last immunizing injection. GA concentrations varied (as indicated) between 0-02 and 0-08%.
Immunization schedule*
- * * *- 0-08(28)-0-02(7)-challenge
--A---------- 0-06(28)-0-02(7)-challenge
-------- A--- 0-04(28)-0-02(7)-challenge
-+ + +-0-02(7)-challenge
untreated-challenge
* The death rate in the group immunized by one injection of 0-02% GA-treated cells was
significantly higher (P< 0-001) than in the control unimmunized group.
Induction of antitumour protection by
immunization with MOPC-315 GA-treated
cells was investigated under various con-
ditions, including GA concentrations used
for treatment, number of immunizing in-
jections, number of cells per injection,
interval between injections and number of
days between the last immunizing injec-
tion and challenge. The results sum-
marized in the Table demonstrate that
immunization with GA-treated MOPC-315
cells induced partial, though significant,
protection against challenge with 104
tumour cells. The antitumour protection
was more marked in groups receiving
more than one immunizing injection,
especially if the first injection was with
cells treated with 0.08% GA. A typical
experiment is illustrated in Fig. 2.
The results show that the effect of GA
was directly proportional to its concentra-
tion: firstly, impairment of dT incorpora-
tion, secondly, loss of tumorigenic ability
and finally, change in trypan-blue dye
exclusion. Correlation between the con-
centration ofGA and the effect on tumour
cells has also been reported by other
workers (Bubbers & Henney, 1975;
Kataoka et al., 1975; Price et al., 1979).
Immunization with MOPC-315 cells
treated with GA afforded partial protec-
tion against tumorigenic challenge. It
would be of interest to devise more
optimal schedules for immunization, and
to clarify the nature of the immune
response in protected and unprotected
animals submitted to a similar schedule of
immunization.
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